Q-omics provides the consensus-scored CDC42EP2 profile across patient tissues and cancer cell-line models. CDC42EP2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CDC42EP2 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, CDC42EP2 protein abundance shows 24,618 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, BLCA, and GBM as cancer lineages where CDC42EP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC42EP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC42EP2 survival associations across molecular data types. CDC42EP2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC42EP2 RNA expression–survival associations across cancer types. High CDC42EP2 expression shows unfavorable associations in LIHC, BLCA, UVM, KIRP, LUAD and OV. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CDC42EP2 RNA expression.
This table summarizes CDC42EP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CDC42EP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC42EP2 shows lower tumor expression in BLCA, THCA, KIRC, KICH and BRCA and higher tumor expression in COAD. The BLCA box plot shows higher CDC42EP2 RNA expression in normal versus tumor tissue (log2 FC = −2.125, t-test p < 0.001).
This table shows molecular features associated with CDC42EP2 in patient tissues and cancer cell lines. In patient samples, CDC42EP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC42EP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
